ViroLogic Awarded NIH Grant to Develop Hepatitis C Virus Drug Resistance Test
SOUTH SAN FRANCISCO, Calif. -- ViroLogic, Inc. announced today that the company has been awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, to develop a Hepatitis C virus (HCV) drug susceptibility assay.
"This grant again reaffirms our leadership and expertise in anti-viral resistance research," said Bill Young, ViroLogic's chairman and CEO. "We believe it also demonstrates how our core competency in virology and assay development can be applied to HCV, a serious chronic viral disease."
Neil Parkin, PhD, scientific director, is the principal investigator of the project, which will focus on the development of rapid and sensitive assays to evaluate the susceptibility of HCV to investigational drugs that inhibit viral polymerase and protease that are both critical for HCV replication. These assays are expected to support the development and characterization of new anti-HCV drugs and the selection of optimal drug regimens for patients undertaking or failing anti-HCV drug therapy.
This latest grant follows the recent announcement of three other NIH grants to ViroLogic and brings the total grant awards announced this quarter to more than $4 million to be funded over three years.
Hepatitis C is one of the most common chronic blood-borne infections in the United States. According to the U.S. Centers for Disease Control and Prevention, approximately 3.9 million Americans are infected with HCV. Currently, no vaccine is available to prevent new HCV infections. Left untreated, chronic HCV infection often leads to end stage liver disease and is the leading reason for liver transplantation in the United States. In contrast to the current treatment of chronic HCV infection, a combination of interferon and ribavirin, the next generations of anti-HCV drugs are designed to target specific viral proteins and directly block critical steps in the HCV replication cycle.
ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. ViroLogic's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses.
Source: ViroLogic, Inc.
Newsletter
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
